 |
|
Regression of Electrocardiographic Left Ventricular Hypertrophy and Decreased Incidence of New-Onset Atrial Fibrillation in Patients With Hypertension
Peter M. Okin, MD;
Kristian Wachtell, MD;
Richard B. Devereux, MD;
Katherine E. Harris, DrPH;
Sverker Jern, MD, PhD;
Sverre E. Kjeldsen, MD, PhD;
Stevo Julius, MD, ScD;
Lars H. Lindholm, MD, PhD;
Markku S. Nieminen, MD, PhD;
Jonathan M. Edelman, MD;
Darcy A. Hille, MS, EMBA;
Björn Dahlöf, MD, PhD
JAMA. 2006;296:1242-1248.
Context Atrial fibrillation (AF) is associated with increased risk of mortality and cardiovascular events, particularly stroke, making prevention of new-onset AF a clinical priority. Although the presence and severity of electrocardiographic left ventricular hypertrophy (LVH) appear to predict development of AF, whether regression of electrocardiographic LVH is associated with a decreased incidence of AF is unclear.
Objective To test the hypothesis that in-treatment regression or continued absence of electrocardiographic LVH during antihypertensive therapy is associated with a decreased incidence of AF, independent of blood pressure and treatment modality.
Design, Setting, and Participants Double-blind, randomized, parallel-group study conducted in 1995-2001 among 8831 men and women with hypertension, aged 55-80 years (median, 67 years), with electrocardiographic LVH by Cornell voltage-duration product or Sokolow-Lyon voltage, with no history of AF, without AF on the baseline electrocardiogram, and enrolled in the Losartan Intervention for Endpoint Reduction in Hypertension Study.
Interventions Losartan- or atenolol-based treatment regimens, with follow-up assessments at 6 months and then yearly until death or study end.
Main Outcome Measure New-onset AF in relation to electrocardiographic LVH determined at baseline and subsequently. Electrocardiographic LVH was measured using sex-adjusted Cornell product criteria ({RaVL + SV3 [+ 6 mm in women]} x QRS duration).
Results After a mean (SD) follow-up of 4.7 (1.1) years, new-onset AF occurred in 290 patients with in-treatment regression or continued absence of Cornell product LVH for a rate of 14.9 per 1000 patient-years and in 411 patients with in-treatment persistence or development of LVH by Cornell product criteria for a rate of 19.0 per 1000 patient-years. In time-dependent Cox analyses adjusted for treatment effects, baseline differences in risk factors for AF, baseline and in-treatment blood pressure, and baseline severity of electrocardiographic LVH, lower in-treatment Cornell product LVH treated as a time-varying covariate was associated with a 12.4% lower rate of new-onset AF (adjusted hazard ratio [HR], 0.88; 95% CI, 0.80-0.97; P = .007) for every 1050 mm x msec (per 1-SD) lower Cornell product, with persistence of the benefit of losartan vs atenolol therapy on developing AF (HR, 0.83; 95% CI, 0.71-0.97; P = .01).
Conclusions Lower Cornell product electrocardiographic LVH during antihypertensive therapy is associated with a lower likelihood of new-onset AF, independent of blood pressure lowering and treatment modality in essential hypertension. These findings suggest that antihypertensive therapy targeted at regression or prevention of electrocardiographic LVH may reduce the incidence of new-onset AF.
Author Affiliations: Greenberg Division of Cardiology, Weill Medical College of Cornell University, New York, NY (Drs Okin and Devereux); Department of Medicine, Glostrup University Hospital, Glostrup, Denmark (Dr Wachtell); Merck Research Laboratories, West Point, Pa (Dr Harris and Ms Hille); Sahlgrenska University Hospital/Östra, Göteborg, Sweden (Drs Jern and Dahlöf); University of Oslo, Ullevål Hospital, Oslo, Norway (Dr Kjeldsen); University of Michigan Medical Center, Ann Arbor (Drs Kjeldsen and Julius); Umeå University, Umeå, Sweden (Dr Lindholm); Division of Cardiology, Department of Medicine, Helsinki University Central Hospital, Helsinki, Finland (Dr Nieminen); and Merck & Co Inc, Whitehouse Station, NJ (Dr Edelman).
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
RELATED LETTERS
Left Ventricular Hypertrophy Regression and Atrial Fibrillation Incidence
Mark H. Hyman
JAMA. 2007;297(1):40.
EXTRACT
| FULL TEXT
Left Ventricular Hypertrophy Regression and Atrial Fibrillation Incidence—Reply
Peter M. Okin and Richard B. Devereux
JAMA. 2007;297(1):40-41.
EXTRACT
| FULL TEXT
Outcomes in Patients With Prolonged PR Interval or First-Degree Atrioventricular Block
Jaewon Oh, Ho Youn Won, and Seok-Min Kang
JAMA. 2009;302(18):1967.
EXTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Outcomes in Patients With Prolonged PR Interval or First-Degree Atrioventricular Block
Oh et al.
JAMA 2009;302:1967-1967.
FULL TEXT
Atrial tissue Doppler imaging for prediction of new-onset atrial fibrillation
De Vos et al.
Heart 2009;95:835-840.
ABSTRACT
| FULL TEXT
Cardiac remodelling and dysfunction in children with obstructive sleep apnoea: a community based study
Chan et al.
Thorax 2009;64:233-239.
ABSTRACT
| FULL TEXT
Prevention of Atrial Fibrillation: Report From a National Heart, Lung, and Blood Institute Workshop
Benjamin et al.
Circulation 2009;119:606-618.
ABSTRACT
| FULL TEXT
Atrial fibrillation, maybe it is not so lone?
Wachtell
J Am Coll Cardiol 2009;53:30-31.
FULL TEXT
Slower Heart Rates for Healthy Hearts: Time to Redefine Tachycardia?
Gopinathannair et al.
Circ Arrhythm Electrophysiol 2008;1:321-323.
FULL TEXT
The left atrium, atrial fibrillation, and the risk of stroke in hypertensive patients with left ventricular hypertrophy
Wachtell et al.
Ther Adv Cardiovasc Dis 2008;2:507-513.
ABSTRACT
Incidence of Atrial Fibrillation in Relation to Changing Heart Rate Over Time in Hypertensive Patients: The LIFE Study
Okin et al.
Circ Arrhythm Electrophysiol 2008;1:337-343.
ABSTRACT
| FULL TEXT
Gender Differences in Regression of Electrocardiographic Left Ventricular Hypertrophy During Antihypertensive Therapy
Okin et al.
Hypertension 2008;52:100-106.
ABSTRACT
| FULL TEXT
The Year in Hypertension
Williams
J Am Coll Cardiol 2008;51:1803-1817.
FULL TEXT
Effect of Lower Targets for Blood Pressure and LDL Cholesterol on Atherosclerosis in Diabetes: The SANDS Randomized Trial
Howard et al.
JAMA 2008;299:1678-1689.
ABSTRACT
| FULL TEXT
Effects of Losartan in Women With Hypertension and Left Ventricular Hypertrophy: Results From the Losartan Intervention For Endpoint Reduction in Hypertension Study
Os et al.
Hypertension 2008;51:1103-1108.
ABSTRACT
| FULL TEXT
In-Treatment Resolution or Absence of Electrocardiographic Left Ventricular Hypertrophy Is Associated With Decreased Incidence of New-Onset Diabetes Mellitus in Hypertensive Patients: The Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) Study
Okin et al.
Hypertension 2007;50:984-990.
ABSTRACT
| FULL TEXT
Left Ventricular Hypertrophy Reversal and Prevention of Diabetes: Two Birds With One Stone?
Schillaci et al.
Hypertension 2007;50:851-853.
FULL TEXT
2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC)
Authors/Task Force Members: et al.
Eur Heart J 2007;0:ehm236v1-75.
FULL TEXT
Pulse Pressure and Risk of New-Onset Atrial Fibrillation
Mitchell et al.
JAMA 2007;297:709-715.
ABSTRACT
| FULL TEXT
Left Ventricular Hypertrophy Regression and Atrial Fibrillation Incidence
Hyman
JAMA 2007;297:40-40.
FULL TEXT
JournalScan
Lindsay
Heart 2007;93:143-144.
FULL TEXT
Hypertension begets hypertrophy begets atrial fibrillation? Insights from yet another sheep model
Kirchhof and Schotten
Eur Heart J 2006;27:2919-2920.
FULL TEXT
Should Antihypertensive Therapy Target Both LVH and BP?
Journal Watch Cardiology 2006;2006:6-6.
FULL TEXT
|
